China National Medicines Corporation Ltd.

Equities

600511

CNE000001D56

Pharmaceuticals

End-of-day quote Shanghai S.E. 06:00:00 2024-04-10 pm EDT 5-day change 1st Jan Change
33.51 CNY +0.84% Intraday chart for China National Medicines Corporation Ltd. -1.15% +17.09%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
China Stocks Muted at Close as Recovery Optimism Fades; Sinopharm Jumps 6% on Upbeat 2023 Earnings MT
Sinopharm's 2023 Profit Climbs 9%; Shares Up 6% MT
China National Medicines Corporation Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
China National Medicines Deputy Manager Under Probe for Alleged Insider Trading MT
CASI Pharmaceuticals, Inc. Enters into an Exclusive Distribution Agreement with China National Medicines Corporation Ltd CI
China National Medicines' Profit Drops 16.1% in Q3 MT
China National Medicines Corporation Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Sinopharm CFO Retires; Successor Named MT
China National Medicines Corporation Ltd.(XSSC:600511) added to S&P Global BMI Index CI
China National Medicines Corporation Ltd.(XSSC:600511) added to FTSE All-World Index CI
China National Medicines' Profit Climbs 14.2% in H1 MT
China National Medicines Corporation Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
China National Medicines' Q1 Profit Rises 10.9% MT
China National Medicines Corporation Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Sinopharm’s Profit Rises 12% in 2022; Revenue Slips 2% MT
China National Medicines' 2022 Profit Up 12% MT
Sinopharm Eyes Production of Merck's COVID-19 Drug in China MT
Sinopharm Clarifies It Is Not A Distributor for Pfizer's COVID-19 Drug MT
Sinopharm to Buy $168 Million Shares in Shyndec Pharma MT
Sinopharm Unit Wins Nod to Launch Clinical Trial of COVID-19 Nasal Drug MT
China National Medicines' Q3 Profit Rises 6% MT
China National Medicines Corporation Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
China National Medicines Unit Isolates Monkeypox Virus, Begins Vaccine Development MT
China National Medicines' H1 Net Profit Rises 13% MT
China National Medicines Corporation Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Chart China National Medicines Corporation Ltd.
More charts
China National Medicines Corporation Ltd. is a China-based company principally engaged in the distribution of pharmaceutical products. The Company's primary products include proprietary Chinese medicines, chemical medicine preparations, chemical raw materials, antibiotics, biochemical drugs, biological products, narcotic drugs, psychotropic drugs, vaccines and health foods, among others. The Company is also involved in the production of pharmaceuticals and the provision of warehousing services through its subsidiaries.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
33.51 CNY
Average target price
42.3 CNY
Spread / Average Target
+26.23%
Consensus

Quarterly revenue - Rate of surprise